Printer Friendly

Teva Confirms Exercise of Option Under Collaboration With IMPAX Laboratories, Inc.

Business/Health Editors


Teva Pharmaceutical Industries Limited (Nasdaq:TEVA) confirmed today that an option relating to an additional product under the strategic alliance between a Teva subsidiary and IMPAX Laboratories, Inc. (Nasdaq:IPXL) has been exercised by Teva.

The agreement, signed in June 2001, granted Teva exclusive United States marketing rights and an option to acquire exclusive marketing rights in Canada and various other Western countries for eleven products, allocated among three tiers which reflected the extent of their development at the time of the agreement, plus an option to acquire exclusive marketing rights to one additional IMPAX product pending approval.

The so called "Tier 1 Products", which were products as to which IMPAX had pending ANDAs at the U.S. Food and Drug Administration (FDA), included: Loratadine/Pseudoephedrine Sulfate 12 hour Extended Release Tablets (generic of Claritin(R) D12), Loratadine/Pseudoephedrine Sulfate 24 hour Extended Release Tablets (generic of Claritin(R) D24), Loratadine Orally Disintegrating Tablets (generic of Claritin(R) Reditabs), Bupropion Extended Release Tablets (generic of Wellbutrin(R) SR Tablets), Bupropion Extended Release Tablets (generic of Zyban(R) Tablets) and Omeprazole Delayed Release Capsules (generic of Prilosec(R) Capsules).

The recent tentative and final approvals received by IMPAX from the FDA for its Omeprazole Delayed Release Capsules ANDA triggered the option.

Mr. Israel Makov, President and CEO of Teva said: "We are pleased with our strategic alliance with IMPAX, and our exercise of this option is part of our ongoing relationship with them under our existing contract. Under this option, we have rights to IMPAX's ANDA for Omeprazole Delayed Release Capsules. However, given the pending lawsuit between IMPAX and AstraZeneca regarding this product, we do not anticipate launching this product until the lawsuit is resolved."

Teva Pharmaceutical Industries Ltd., headquartered in Israel, is among the top 35 pharmaceutical companies and among the largest generic pharmaceutical companies in the world. Over 80% of Teva's sales are in North America and Europe. The company develops, manufactures and markets generic and innovative human pharmaceuticals and active pharmaceutical ingredients.

IMPAX Laboratories, Inc. is a technology based specialty pharmaceutical company applying its formulation expertise and drug delivery technology to the development of controlled-release and niche generics in addition to the development of branded products. IMPAX markets its generic products through its Global Pharmaceuticals division and intends to market its branded products through the IMPAX Pharmaceuticals division. IMPAX Laboratories is headquartered in Hayward, California, and has a full range of capabilities in its Hayward and Philadelphia facilities.

Safe Harbor Statement under the U. S. Private Securities Litigation Reform Act of 1995: This release contains forward-looking statements, which express the current beliefs and expectations of management. Such statements are based on current expectations and involve a number of known and unknown risks and uncertainties that could cause Teva's future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include Teva's ability to successfully develop and commercialize additional pharmaceutical products, the introduction of competitive generic products, the impact of competition from brand-name companies that sell their own generic products or successfully extend the exclusivity period of their branded products, Teva's ability to rapidly integrate the operations of acquired businesses, the availability of product liability coverage in the current insurance market, the impact of pharmaceutical industry regulation and pending legislation that could affect the pharmaceutical industry, the difficulty of predicting U.S. Food and Drug Administration ("FDA") and other regulatory authority approvals, the regulatory environment and changes in the health policies and structure of various countries, acceptance and demand for new pharmaceutical products and new therapies, uncertainties regarding market acceptance of innovative products newly launched, currently being sold or in development, the impact of restructuring of clients, reliance on strategic alliances, exposure to product liability claims, dependence on patent and other protections for innovative products, fluctuations in currency, exchange and interest rates, operating results and other factors that are discussed in Teva's Annual Report on Form 20-F and its other filings with the U.S. Securities and Exchange Commission ("SEC"). Forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to update publicly or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.
COPYRIGHT 2002 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2002, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:1USA
Date:Nov 26, 2002
Previous Article:Aetna Announces Appearance At Merrill Lynch Health Services Investor Conference.
Next Article:NYLIM Retirement Plan Services Appoints Industry Veteran Gary Jackson as Managing Director of Sales.

Related Articles
IMPAX and Teva Announce Strategic Alliance for Generic Controlled Release Products.
IMPAX Receives $3.75 Million Investment From Teva Pharmaceutical.
IMPAX Receives $3.75 Million Investment from Teva Pharmaceutical.
IMPAX Receives $3.75 Million Investment From Teva Pharmaceutical.
IMPAX Receives $3.75 Million Investment From Teva Pharmaceutical.
IMPAX and Teva Launch Omeprazole Delayed Release Capsules 20mg.
IMPAX Provides Updates on Progress to File 10-K and Related Matters.
IMPAX Receives Final FDA Approval and First-to-File Status for Generic Version of Ditropan(R) XL 15 mg.
IMPAX Announces FDA Approval of Generic Wellbutrin XL 300 mg.
IMPAX Files Revised Submission with Office of the Chief Accountant of the SEC.

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters